Impact of human papillomavirus on distant metastatic failure patterns in squamous cell cancer of the oropharynx in patients treated with chemoradiation
HPV initiated ( HPV+ ) squamous cell carcinoma of oropharynx ( SCCOP ) has a unique epidemiology, biology, and genetic profile compared to HPV- disease and is associated with excellent outcomes after chemoradiation Whether there are differences in the patterns and timing of distant metastatic failure in HPV+ disease is unclear.
Researchers have reviewed 285 patients with stage III-IV squamous cell carcinoma of oropharynx treated with chemoradiation between 2002-2013 from an IRB approved registry. 27/245 HPV+ and 8/40 HPV- adult patients ( pts ) who failed with distant metastases were identified.
HPV positivity was determined by in situ hybridization for HPV DNA and/or by strong and diffuse ( greater than 75% ) staining for p16 immunohistochemistry.
Radiotherapy was performed using either 3DRT ( 15/27 HPV+, 4/8 HPV- ) or intensity modulated radiation therapy ( 12/27 HPV+, 4/8 HPV- ) with doses from 66-79 Gy.
Concurrent chemotherapy was given with Cisplatin ( 9/27 HPV+, 2/8 HPV- ), Cisplatin / 5FU ( 10/27 HPV+, 3/8 HPV- ), or Cetuximab ( 8/27 HPV+, 2/8 HPV- ).
One HPV- patient received chemotherapy with Cisplatin / Paclitaxel. One patient in each group was treated with adjuvant chemoradiotherapy after initial resection.
While the distant metastasis rate for HPV+ vs HPV- squamous cell carcinoma of oropharynx was similar ( 11% vs 20% ), the mean time to develop distant metastasis was significantly longer after the completion of treatment for HPV+ patients ( 21.6 months, range 2.7-79.8 ) than for HPV- patients ( 7.0 months, range 2.1-14.4; p=0.03 ).
The most common site of metastasis in both HPV+ and HPV- patients was the lung ( 17/27 HPV+, 5/8 HPV- ) followed by bone ( 12/27 HPV+, 2/8 HPV- ).
The average number of metastatic subsites involved was significantly higher for HPV+ patients than HPV- pts ( 2.0 vs 1.1; p = 0.026 ).
Of the HPV+ patients, 21/27 ( 78% ) presented with greater than 1 metastatic deposit, and 12/27 ( 44% ) had distant metastasis involving greater than 1 organ system, compared to only 1/8 ( 12.5% ) HPV-patients.
Dissemination to less typical metastatic sites was common in HPV+ patients, including liver ( 6 ), intra-abdominal lymph nodes ( 3 ), brain ( 2 ), pleura ( 2 ), and peritoneum ( 1 ).
Only 4/27 (15%) HPV+ patients also had locoregional failure at any point during their post-treatment course vs 3/8 ( 38% ) HPV-patients.
In conclusion, while the rates of distant metastasis appear similar between pts with HPV+ and HPV- squamous cell carcinoma of oropharynx treated with chemoradiotherapy, distant metastasis occur significantly later and involves more subsites in the HPV+ group.
HPV+ distant metastasis failure appears to more frequently involve sites that are atypical for smoking related head and neck cancer.
Distant metastasis disease in HPV+ squamous cell carcinoma of oropharynx has unique characteristics and a unique natural history that may require alternative treatment strategies. ( Xagena )
Source: Multidisciplinary Head and Neck Cancer Symposium, 2014
Keytruda plus Lenvima combination for patients with certain types of advanced endometrial carcinoma - FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1...
As part of an ongoing phase Ib/II study ( NCT02501096 ) in patients with selected solid tumors, Lenvatinib [ Lenvima...
Management of hepatocellular carcinoma with portal vein tumor thrombus: new evidence and perspectives
Hepatocellular carcinoma ( HCC ) is responsible for over 600,000 deaths annually. In addition, hepatocellular carcinoma is characterized by its...
Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after Platinum-containing chemotherapy
The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1...
Abraxane for first-line treatment of patients with non-small cell lung cancer, positive CHMP opinion
The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...
The aim of American Society of Clinical Oncology ( ASCO ) Clinical Practice Guideline is to provide evidence-based recommendations to...
LABC ( Locally advanced breast cancer ) occurs at first presentation in about one-fifth of breast cancer patients worldwide, with...
Glioblastoma ( GBM ) is the most common primary malignant adult brain tumor and, despite treatment advances in recent years,...
Although anti–CTLA-4 and anti–PD-1 monoclonal antibodies ( mAbs ) may overcome T-cell suppression, T-cell activation depends on the engagement of...